Global Cancer Stem Cells (CSCs) 麻豆原创 Research Report 2023

Publication ID:

PB504231808

Publication Date:

April 6, 2023

Pages:

117

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Highlights
The global Cancer Stem Cells (CSCs) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Cancer Stem Cells (CSCs) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cancer Stem Cells (CSCs) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Cancer Stem Cells (CSCs) include Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee and Fluxion, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Stem Cells (CSCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Stem Cells (CSCs).
The Cancer Stem Cells (CSCs) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cancer Stem Cells (CSCs) market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Stem Cells (CSCs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Creatv MicroTech
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
Aviva Biosciences Corporation
ScreenCell
Silicon Biosystems
Segment by Type
CellSearch
Others
Segment by Application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Stem Cells (CSCs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Stem Cells (CSCs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Cancer Stem Cells (CSCs) 麻豆原创 Overview
1.1 Product Overview and Scope of Cancer Stem Cells (CSCs)
1.2 Cancer Stem Cells (CSCs) Segment by Type
1.2.1 Global Cancer Stem Cells (CSCs) 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 CellSearch
1.2.3 Others
1.3 Cancer Stem Cells (CSCs) Segment by Application
1.3.1 Global Cancer Stem Cells (CSCs) 麻豆原创 Value by Application: (2023-2029)
1.3.2 Breast Cancer Diagnosis and Treatment
1.3.3 Prostate Cancer Diagnosis and Treatment
1.3.4 Colorectal Cancer Diagnosis and Treatment
1.3.5 Lung Cancer Diagnosis and Treatment
1.3.6 Other Cancers Diagnosis and Treatment
1.4 Global Cancer Stem Cells (CSCs) 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Cancer Stem Cells (CSCs) Revenue 2018-2029
1.4.2 Global Cancer Stem Cells (CSCs) Sales 2018-2029
1.4.3 Global Cancer Stem Cells (CSCs) 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Cancer Stem Cells (CSCs) 麻豆原创 Competition by Manufacturers
2.1 Global Cancer Stem Cells (CSCs) Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Cancer Stem Cells (CSCs) Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Cancer Stem Cells (CSCs) Average Price by Manufacturers (2018-2023)
2.4 Global Cancer Stem Cells (CSCs) Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Cancer Stem Cells (CSCs), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Stem Cells (CSCs), Product Type & Application
2.7 Cancer Stem Cells (CSCs) 麻豆原创 Competitive Situation and Trends
2.7.1 Cancer Stem Cells (CSCs) 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cancer Stem Cells (CSCs) Players 麻豆原创 Share by Revenue
2.7.3 Global Cancer Stem Cells (CSCs) 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Stem Cells (CSCs) Retrospective 麻豆原创 Scenario by Region
3.1 Global Cancer Stem Cells (CSCs) 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Cancer Stem Cells (CSCs) Global Cancer Stem Cells (CSCs) Sales by Region: 2018-2029
3.2.1 Global Cancer Stem Cells (CSCs) Sales by Region: 2018-2023
3.2.2 Global Cancer Stem Cells (CSCs) Sales by Region: 2024-2029
3.3 Global Cancer Stem Cells (CSCs) Global Cancer Stem Cells (CSCs) Revenue by Region: 2018-2029
3.3.1 Global Cancer Stem Cells (CSCs) Revenue by Region: 2018-2023
3.3.2 Global Cancer Stem Cells (CSCs) Revenue by Region: 2024-2029
3.4 North America Cancer Stem Cells (CSCs) 麻豆原创 Facts & Figures by Country
3.4.1 North America Cancer Stem Cells (CSCs) 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Cancer Stem Cells (CSCs) Sales by Country (2018-2029)
3.4.3 North America Cancer Stem Cells (CSCs) Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Cancer Stem Cells (CSCs) 麻豆原创 Facts & Figures by Country
3.5.1 Europe Cancer Stem Cells (CSCs) 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Cancer Stem Cells (CSCs) Sales by Country (2018-2029)
3.5.3 Europe Cancer Stem Cells (CSCs) Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Stem Cells (CSCs) 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Cancer Stem Cells (CSCs) 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Cancer Stem Cells (CSCs) Sales by Country (2018-2029)
3.6.3 Asia Pacific Cancer Stem Cells (CSCs) Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Cancer Stem Cells (CSCs) 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Cancer Stem Cells (CSCs) 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Cancer Stem Cells (CSCs) Sales by Country (2018-2029)
3.7.3 Latin America Cancer Stem Cells (CSCs) Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Stem Cells (CSCs) 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Stem Cells (CSCs) 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Cancer Stem Cells (CSCs) Sales by Country (2018-2029)
3.8.3 Middle East and Africa Cancer Stem Cells (CSCs) Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Cancer Stem Cells (CSCs) Sales by Type (2018-2029)
4.1.1 Global Cancer Stem Cells (CSCs) Sales by Type (2018-2023)
4.1.2 Global Cancer Stem Cells (CSCs) Sales by Type (2024-2029)
4.1.3 Global Cancer Stem Cells (CSCs) Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Cancer Stem Cells (CSCs) Revenue by Type (2018-2029)
4.2.1 Global Cancer Stem Cells (CSCs) Revenue by Type (2018-2023)
4.2.2 Global Cancer Stem Cells (CSCs) Revenue by Type (2024-2029)
4.2.3 Global Cancer Stem Cells (CSCs) Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Cancer Stem Cells (CSCs) Price by Type (2018-2029)
5 Segment by Application
5.1 Global Cancer Stem Cells (CSCs) Sales by Application (2018-2029)
5.1.1 Global Cancer Stem Cells (CSCs) Sales by Application (2018-2023)
5.1.2 Global Cancer Stem Cells (CSCs) Sales by Application (2024-2029)
5.1.3 Global Cancer Stem Cells (CSCs) Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Cancer Stem Cells (CSCs) Revenue by Application (2018-2029)
5.2.1 Global Cancer Stem Cells (CSCs) Revenue by Application (2018-2023)
5.2.2 Global Cancer Stem Cells (CSCs) Revenue by Application (2024-2029)
5.2.3 Global Cancer Stem Cells (CSCs) Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Cancer Stem Cells (CSCs) Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Janssen
6.1.1 Janssen Corporation Information
6.1.2 Janssen Description and Business Overview
6.1.3 Janssen Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Janssen Cancer Stem Cells (CSCs) Product Portfolio
6.1.5 Janssen Recent Developments/Updates
6.2 Qiagen
6.2.1 Qiagen Corporation Information
6.2.2 Qiagen Description and Business Overview
6.2.3 Qiagen Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Qiagen Cancer Stem Cells (CSCs) Product Portfolio
6.2.5 Qiagen Recent Developments/Updates
6.3 Advanced Cell Diagnostics
6.3.1 Advanced Cell Diagnostics Corporation Information
6.3.2 Advanced Cell Diagnostics Description and Business Overview
6.3.3 Advanced Cell Diagnostics Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Advanced Cell Diagnostics Cancer Stem Cells (CSCs) Product Portfolio
6.3.5 Advanced Cell Diagnostics Recent Developments/Updates
6.4 ApoCell
6.4.1 ApoCell Corporation Information
6.4.2 ApoCell Description and Business Overview
6.4.3 ApoCell Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 ApoCell Cancer Stem Cells (CSCs) Product Portfolio
6.4.5 ApoCell Recent Developments/Updates
6.5 Biofluidica
6.5.1 Biofluidica Corporation Information
6.5.2 Biofluidica Description and Business Overview
6.5.3 Biofluidica Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Biofluidica Cancer Stem Cells (CSCs) Product Portfolio
6.5.5 Biofluidica Recent Developments/Updates
6.6 Clearbridge Biomedics
6.6.1 Clearbridge Biomedics Corporation Information
6.6.2 Clearbridge Biomedics Description and Business Overview
6.6.3 Clearbridge Biomedics Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Clearbridge Biomedics Cancer Stem Cells (CSCs) Product Portfolio
6.6.5 Clearbridge Biomedics Recent Developments/Updates
6.7 CytoTrack
6.6.1 CytoTrack Corporation Information
6.6.2 CytoTrack Description and Business Overview
6.6.3 CytoTrack Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 CytoTrack Cancer Stem Cells (CSCs) Product Portfolio
6.7.5 CytoTrack Recent Developments/Updates
6.8 Celsee
6.8.1 Celsee Corporation Information
6.8.2 Celsee Description and Business Overview
6.8.3 Celsee Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Celsee Cancer Stem Cells (CSCs) Product Portfolio
6.8.5 Celsee Recent Developments/Updates
6.9 Fluxion
6.9.1 Fluxion Corporation Information
6.9.2 Fluxion Description and Business Overview
6.9.3 Fluxion Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Fluxion Cancer Stem Cells (CSCs) Product Portfolio
6.9.5 Fluxion Recent Developments/Updates
6.10 Gilupi
6.10.1 Gilupi Corporation Information
6.10.2 Gilupi Description and Business Overview
6.10.3 Gilupi Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Gilupi Cancer Stem Cells (CSCs) Product Portfolio
6.10.5 Gilupi Recent Developments/Updates
6.11 Cynvenio
6.11.1 Cynvenio Corporation Information
6.11.2 Cynvenio Cancer Stem Cells (CSCs) Description and Business Overview
6.11.3 Cynvenio Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Cynvenio Cancer Stem Cells (CSCs) Product Portfolio
6.11.5 Cynvenio Recent Developments/Updates
6.12 On-chip
6.12.1 On-chip Corporation Information
6.12.2 On-chip Cancer Stem Cells (CSCs) Description and Business Overview
6.12.3 On-chip Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.12.4 On-chip Cancer Stem Cells (CSCs) Product Portfolio
6.12.5 On-chip Recent Developments/Updates
6.13 YZY Bio
6.13.1 YZY Bio Corporation Information
6.13.2 YZY Bio Cancer Stem Cells (CSCs) Description and Business Overview
6.13.3 YZY Bio Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.13.4 YZY Bio Cancer Stem Cells (CSCs) Product Portfolio
6.13.5 YZY Bio Recent Developments/Updates
6.14 BioView
6.14.1 BioView Corporation Information
6.14.2 BioView Cancer Stem Cells (CSCs) Description and Business Overview
6.14.3 BioView Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.14.4 BioView Cancer Stem Cells (CSCs) Product Portfolio
6.14.5 BioView Recent Developments/Updates
6.15 Creatv MicroTech
6.15.1 Creatv MicroTech Corporation Information
6.15.2 Creatv MicroTech Cancer Stem Cells (CSCs) Description and Business Overview
6.15.3 Creatv MicroTech Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Creatv MicroTech Cancer Stem Cells (CSCs) Product Portfolio
6.15.5 Creatv MicroTech Recent Developments/Updates
6.16 Fluidigm
6.16.1 Fluidigm Corporation Information
6.16.2 Fluidigm Cancer Stem Cells (CSCs) Description and Business Overview
6.16.3 Fluidigm Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Fluidigm Cancer Stem Cells (CSCs) Product Portfolio
6.16.5 Fluidigm Recent Developments/Updates
6.17 Ikonisys
6.17.1 Ikonisys Corporation Information
6.17.2 Ikonisys Cancer Stem Cells (CSCs) Description and Business Overview
6.17.3 Ikonisys Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Ikonisys Cancer Stem Cells (CSCs) Product Portfolio
6.17.5 Ikonisys Recent Developments/Updates
6.18 AdnaGen
6.18.1 AdnaGen Corporation Information
6.18.2 AdnaGen Cancer Stem Cells (CSCs) Description and Business Overview
6.18.3 AdnaGen Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.18.4 AdnaGen Cancer Stem Cells (CSCs) Product Portfolio
6.18.5 AdnaGen Recent Developments/Updates
6.19 IVDiagnostics
6.19.1 IVDiagnostics Corporation Information
6.19.2 IVDiagnostics Cancer Stem Cells (CSCs) Description and Business Overview
6.19.3 IVDiagnostics Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.19.4 IVDiagnostics Cancer Stem Cells (CSCs) Product Portfolio
6.19.5 IVDiagnostics Recent Developments/Updates
6.20 Miltenyi Biotec
6.20.1 Miltenyi Biotec Corporation Information
6.20.2 Miltenyi Biotec Cancer Stem Cells (CSCs) Description and Business Overview
6.20.3 Miltenyi Biotec Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Miltenyi Biotec Cancer Stem Cells (CSCs) Product Portfolio
6.20.5 Miltenyi Biotec Recent Developments/Updates
6.21 Aviva Biosciences Corporation
6.21.1 Aviva Biosciences Corporation Corporation Information
6.21.2 Aviva Biosciences Corporation Cancer Stem Cells (CSCs) Description and Business Overview
6.21.3 Aviva Biosciences Corporation Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Aviva Biosciences Corporation Cancer Stem Cells (CSCs) Product Portfolio
6.21.5 Aviva Biosciences Corporation Recent Developments/Updates
6.22 ScreenCell
6.22.1 ScreenCell Corporation Information
6.22.2 ScreenCell Cancer Stem Cells (CSCs) Description and Business Overview
6.22.3 ScreenCell Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.22.4 ScreenCell Cancer Stem Cells (CSCs) Product Portfolio
6.22.5 ScreenCell Recent Developments/Updates
6.23 Silicon Biosystems
6.23.1 Silicon Biosystems Corporation Information
6.23.2 Silicon Biosystems Cancer Stem Cells (CSCs) Description and Business Overview
6.23.3 Silicon Biosystems Cancer Stem Cells (CSCs) Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Silicon Biosystems Cancer Stem Cells (CSCs) Product Portfolio
6.23.5 Silicon Biosystems Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Stem Cells (CSCs) Industry Chain Analysis
7.2 Cancer Stem Cells (CSCs) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Stem Cells (CSCs) Production Mode & Process
7.4 Cancer Stem Cells (CSCs) Sales and 麻豆原创ing
7.4.1 Cancer Stem Cells (CSCs) Sales Channels
7.4.2 Cancer Stem Cells (CSCs) Distributors
7.5 Cancer Stem Cells (CSCs) Customers
8 Cancer Stem Cells (CSCs) 麻豆原创 Dynamics
8.1 Cancer Stem Cells (CSCs) Industry Trends
8.2 Cancer Stem Cells (CSCs) 麻豆原创 Drivers
8.3 Cancer Stem Cells (CSCs) 麻豆原创 Challenges
8.4 Cancer Stem Cells (CSCs) 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Creatv MicroTech
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
Aviva Biosciences Corporation
ScreenCell
Silicon Biosystems

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.